Free Technical Reports on Novavax and Three Additional Biotech Equities

Stock Research Monitor: NBRV, NBIX, and NVO

LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on NVAX sign up now at www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 7,502.67, down 0.86%; the Dow Jones Industrial Average edged 0.54% higher/ lower, to finish at 24,174.82; and the S&P 500 closed at 2,713.22, marginally slipping 0.49%. US markets saw four out of nine sectors finishing the day in red, four in green, and one in neutral territory. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Nabriva Therapeutics

Dublin, Ireland headquartered Nabriva Therapeutics PLC’s stock finished Tuesday’s session flat at $3.45 with a total trading volume of 165,720 shares. The Company’s shares are trading below their 50-day moving average by 23.15%. Moreover, shares of Nabriva Therapeutics, which engages in the research and development of anti-infective agents to treat infections in humans, have a Relative Strength Index (RSI) of 26.40. Get the full research report on NBRV for free by clicking below at:

www.wallstequities.com/registration/?symbol=NBRV

Neurocrine Biosciences

Shares in San Diego, California headquartered Neurocrine Biosciences Inc. declined 0.18%, ending last Tuesday’s session at $99.10 with a total trading volume of 321,872 shares. The stock has gained 23.92% in the previous three months and 111.89% over the past twelve months. The Company’s shares are trading above their 50-day and 200-day moving averages by 6.29% and 24.52%, respectively. Moreover, shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US, have an RSI of 54.65. Today’s complimentary research report on NBIX is accessible at:

www.wallstequities.com/registration/?symbol=NBIX

Novavax

On Tuesday, Gaithersburg, Maryland headquartered Novavax Inc.’s stock saw a drop/ decline of 2.33%, to close the day at $1.36. A total volume of 1.94 million shares was traded. The Company’s shares have advanced 18.35% over the last twelve months. The stock is trading below its 50-day moving average by 15.11%. Additionally, shares of Novavax, which together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, have an RSI of 31.82. Register now for your free research document on NVAX at:

www.wallstequities.com/registration/?symbol=NVAX

Novo Nordisk

Shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S ended the day 0.45% higher at $46.97. A total volume of 1.15 million shares was traded. The stock has gained 10.34% over the last twelve months. The Company’s shares are trading below their 50-day moving average by 0.22%. Furthermore, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 56.03. Click on the link below and see our free report NVO at:

www.wallstequities.com/registration/?symbol=NVO

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 504469